Preliminary programme
Please, note that the Conference agenda may still undergo minor changes due to organizational reasons.
08:45-09:00
Welcome
Flora Peyvandi (Italy), Pier Mannuccio Mannucci (Italy)
HAEMOPHILIA – CLINICAL SESSION
Chairs: Brian O’Mahony (Ireland), Peter Lenting (France)
09:00-09:20
What we have achieved with the available products and what is needed?
Glenn Pierce (USA)
09:20-09:40
Oral factor VIII (FVIII) bispecific for haemophilia A
Jan Astermark (Sweden)
09:40-10:00
FVIII mimetics – How different are these products and for which bleeding disorders can be used?
Peter Lenting (France)
10:00-10:15
Discussion
10:15-10:45
Coffee break
VWF – RESEARCH SESSION
Chairs: Maha Othman (Canada), Omid Seidizadeh (Italy)
10:45-11:05
The role of the A1 domain in regulating VWF clearance
James O’Donnell (UK)
11:05-11:25
The use of artificial intelligence to interfere with VWF-platelet interactions: diagnosis and management of VWD type 2 and PLT-VWD
Maha Othman (Canada)
11:25-11:45
Which VWF domains are dispensable?
Tom McKinnon (UK)
11:45-12:00
Discussion
SATELLITE SYMPOSIUM
12:00-13:00
Sponsored by Sanofi
PROGRAMME
13:00-14:00
Lunch
SATELLITE LECTURE
14:00-14:30
Sponsored by Roche
PROGRAMME
SATELLITE LECTURE
14:30-15:00
Sponsored by BioMarin
PROGRAMME
THROMBOTIC MICROANGIOPATHIES
Chairs: Bernhard Lämmle (Switzerland), Jan Voorberg (The Netherlands)
15:00-15:20
TTP guidelines: what needs to be changed?
Bernhard Lämmle (Switzerland)
15:20-15:40
The “missed” TTP diagnosis
Paul Coppo (France)
15:40-16:00
Could the conformation of the protease predict recurrence and severity of TTP? Overview of basic science of TTP and future developments (CAR-T cells?)
Karen Vanhoorelbeke (Belgium)
16:00-16:20
Complement and atypical hemolytic uremic syndrome: present and future developments
Massimo Cugno (Italy)
16:20-16:40
Discussion
16:40-17:00
Coffee break
ORAL COMMUNICATIONS
Chairs: Caterina Casari (France), David Lillicrap (Canada)
17:00-17:10
Endonuclease-mediated genomic insertion of AAV-delivered FVIII transgene into hepatocyte safe-harbor locus restores durable FVIII activity in vivo
Jacob Lund (Denmark)
17:10-17:20
Novel vascularised gut-on-a-chip model reveals distinct patterns of dysregulated angiogenesis in VWD
Adela Constantinescu-Bercu (UK)
17:20-17:30
Beyond haemostasis: novel roles of ADAMTS13 in blood and vascular development
Ignacio Babiloni Chust (Italy)
17:30-17:40
Complement overactivation and exocytosis of Weibel-Palade bodies (WPB) promote endothelial thrombogenicity in STEC-HUS
Donata Santarsiero (Italy)
17:40-17:50
Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: second interim analysis from a phase 3b continuation study
Paul Coppo (France)
17:50-18:00
First-in-human study of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease
Priyanka Raheja (United Kingdom)
18:00-18:50
E-POSTER SESSION
PROGRAMME